GIBF

Globally, the rise of more informed healthcare consumers, new technologies, and ubiquity of data and analytics continues to blur the traditional boundaries between therapeutics, medical technologies, consumer devices and information technology (IT). This rapidly evolving superfluid market is putting pressure on the life sciences (LS) companies to change their business models and personalize their products and services. The question life sciences companies must address urgently is how they should be preparing themselves for the coming future. BioAsia 2020 explores the capabilities that Life sciences companies should invest in Today to thrive and create value Tomorrow.